Company Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 18/06/2024 BST 5-day change 1st Jan Change
1,039 USD -0.60% Intraday chart for Regeneron Pharmaceuticals, Inc. +2.83% +18.31%

Business Summary

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:

- revenues from product sales (56.6%);

- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);

- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.

At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Number of employees: 13,677

Sales per Business

USD in Million2022Weight2023Weight Delta
Medicines
100.0 %
12,173 100.0 % 13,117 100.0 % +7.76%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
51.5 %
6,821 56.0 % 6,754 51.5 % -0.98%
Rest of World
44.4 %
4,987 41.0 % 5,827 44.4 % +16.85%
Other
4.1 %
365 3.0 % 536 4.1 % +46.84%

Managers

Managers TitleAgeSince
Founder 64 07/01/88
Chief Executive Officer 71 07/01/88
Director of Finance/CFO 53 31/12/02
Compliance Officer - 31/12/21
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 66 31/12/98
Chief Tech/Sci/R&D Officer 67 31/12/90
Chief Operating Officer - 31/12/97
Chief Tech/Sci/R&D Officer - 31/12/18
Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 71 11/11/10
Chief Executive Officer 71 07/01/88
Director/Board Member 83 31/05/91
Director/Board Member 83 31/05/91
Director/Board Member 74 07/01/88
Founder 64 07/01/88
Director/Board Member 81 31/12/02
Director/Board Member 63 16/02/17
Director/Board Member 66 07/09/23
Director/Board Member 61 11/09/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,818,146 0 0 78.42 %
Stock B 1 134,167,357 106,638,643 ( 79.48 %) 25,800,000 ( 19.23 %)

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
9.958 %
10,791,388 9.958 % 10 577 M $
Vanguard Fiduciary Trust Co.
8.241 %
8,930,241 8.241 % 8 753 M $
JPMorgan Investment Management, Inc.
7.124 %
7,720,152 7.124 % 7 567 M $
BlackRock Advisors LLC
6.129 %
6,641,738 6.129 % 6 510 M $
4,841,548 4.468 % 4 745 M $
Capital Research & Management Co. (World Investors)
4.295 %
4,654,855 4.295 % 4 563 M $
Capital Research & Management Co. (International Investors)
2.887 %
3,129,010 2.887 % 3 067 M $
Geode Capital Management LLC
2.193 %
2,376,591 2.193 % 2 329 M $
Dodge & Cox
2.178 %
2,359,864 2.178 % 2 313 M $
BlackRock Life Ltd.
1.617 %
1,752,379 1.617 % 1 718 M $
NameEquities%Valuation
1,725,565 82.56 % 1 691 M $
42,750 2.045 % 42 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000230 %
14,944 0.000230 % 241 567 $
Bram Bradesco Asset Management S/A DTVM
0.000215 %
13,968 0.000215 % 225 790 $

Company contact information

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

10591-6707, Tarrytown

+914 847 7000

http://www.regeneron.com
address Regeneron Pharmaceuticals, Inc.(REGN)

Group companies

NameCategory and Sector
Biotechnology
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Company Regeneron Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW